Carbetapentane

Trade Names:
Solotuss
- Suspension 30 mg per 5 mL

Pharmacology

Centrally acting antitussive. Temporarily controls and suppresses the cough reflex by selectively depressing the medullary cough center.

Indications and Usage

Symptomatic relief of cough associated with the common cold, sinusitis, allergic rhinitis, and other upper respiratory tract conditions.

Contraindications

Newborns; breast-feeding mothers; hypersensitivity to any component of the product.

Dosage and Administration

PO 30 to 60 mg (5 to 10 mL; 1 to 2 tsp) every 12 h.

PO 15 to 30 mg (2.5 to 5 mL; ½ to 1 tsp) every 12 h.

PO 7.5 to 15 mg (1.25 to 2.5 mL; ¼ to ½ tsp) every 12 h.

General Advice

• Shake suspension well before measuring dose.

Storage/Stability

Store at 59° to 86°F. Protect from freezing.

Drug Interactions

Additive CNS depressant effects may occur.

Do not use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Laboratory Test Interactions

None well documented.

Adverse Reactions

GI

Nausea and other GI disturbances.

Precautions

Pregnancy

Category C .

Lactation

Undetermined.

Children

Safety and efficacy not determined in children younger than 2 yr of age.

Elderly

Patients older than 60 yr of age are more likely to have adverse reactions.

Special Risk Patients

Use with caution in patients with CV disease, diabetes, hypertension, hyperthyroidism, narrow-angle glaucoma, or prostatic hypertrophy.

Phenylketonuria

Product contains phenylalanine.

Overdosage

Symptoms

Central excitement and mental confusion. Patients older than 60 yr of age are more likely to experience CNS depression, convulsions, death, and hallucinations.

Patient Information

• Instruct patient to consult health care provider if cough persists for more than 1 wk, tends to recur, or is accompanied by a high fever, rash, or persistent headache.
• Advise patient to shake suspension well before administering dose.
• Advise phenylketonuria patients that this medication contains phenylalanine 7 mg per mL.